Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...
Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...
In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results